Candel Therapeutics, Inc. develops clinical-stage multimodal biological immunotherapies for cancer, including off-the-shelf viral immunotherapy platforms based on genetically modified adenovirus and herpes simplex virus constructs. Company news commonly covers aglatimagene besadenovec, also called aglatne or CAN-2409, in prostate cancer and non-small cell lung cancer, and linoserpaturev, or CAN-3110, from its HSV platform in recurrent high-grade glioma.
Updates also include clinical-data presentations, FDA designations or clearances, research-and-development communications, quarterly financial results, financing activity, and Nasdaq inducement grants under the company’s equity plans.
Candel Therapeutics (Nasdaq: CADL) reported a wider third-quarter net loss and now plans its prostate cancer approval submission for mid-2027. The planned biologics license application for aglatimagene depends on ongoing FDA dialogue and timelines for assay refinement. Third-quarter 2026 net loss was $21.9 million, versus $11.3 million a year earlier; research and development and administrative expenses increased.
Cash was $203.1 million at September 30, 2026, versus $119.7 million at year-end 2025; Candel expects funding into Q2 2028. Prostate cancer studies reported immune activation and improved recurrence outcomes. Published lung cancer phase 2a results showed median overall survival of 24.5 months in evaluable patients. Updated linoserpaturev glioma cohorts reported median overall survival of 12.0 and 14.3 months; repeat-dosing data remain immature. Manufacturing validation batches are undergoing testing.
Candel Therapeutics (CADL) presented clinical and immune-response data for aglatimagene and linoserpaturev across three cancer programs at SITC 2026. In phase 2 localized prostate cancer testing, aglatimagene increased circulating cancer-fighting T cells; activated cells remained above baseline through Weeks 16-18. Vector DNA detection was transient, with urine clearance at Weeks 16-18. Candel plans to include these findings in its biologics license application for aglatimagene.
In phase 2a non-squamous lung cancer, median overall survival was 25.4 months; immune changes were associated with longer survival, without establishing causation. The phase 3 AURORA trial is ongoing. Phase 1b linoserpaturev median overall survival was 12.0 months in Arms A+B and 14.3 months in repeat-administration Arm C. Arm C data remain immature. An exploratory analysis of subsequent bevacizumab use did not establish a survival benefit.
Candel Therapeutics (Nasdaq: CADL) granted General Counsel Maria Ostrovsky options covering 315,000 common shares on November 3, 2026. The options have an exercise price of $8.82 per share, equal to the stock’s closing price on The Nasdaq Global Market that day.
The employment inducement award was granted under the company’s 2025 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). It vests as to 25% of the underlying shares on the first anniversary of Ostrovsky’s start date, with the remaining 75% vesting in 36 equal monthly installments thereafter. All vesting requires continued service through the applicable vesting date.
Candel Therapeutics (CADL) granted four new employees stock options covering 107,600 common shares on October 31, 2026, as employment inducements.
The options have an $8.33 per-share exercise price and were granted under the 2025 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). Vesting begins with 25% on the first anniversary of each employee's start date; the remaining 75% vests in 36 equal monthly installments thereafter. All vesting requires continued service through the applicable vesting date.
Candel Therapeutics (CADL) announced acceptance of a late-breaking abstract from its phase 2 PrTK05 prostate cancer trial for presentation at SITC 2026.
The November 7, 2026 poster in Phoenix will feature immune changes over time, distribution in the body and viral shedding data for aglatimagene besadenovec in localized intermediate-risk prostate cancer. Chief Scientific Officer Francesca Barone will present abstract 1172.
Candel Therapeutics (CADL) will participate in investor conference discussions and one-on-one meetings in November 2026, represented by CEO Paul Peter Tak.
The Stifel Healthcare Conference session in New York is November 10 at 9:20 AM ET. The Jefferies Global Healthcare Conference session in London is November 18 at 8:30 AM GMT / 3:30 AM ET. Live webcasts will be available on Candel’s website, with replays archived for up to 90 days.
Candel Therapeutics (CADL) appointed Maria Ostrovsky as General Counsel, effective November 3, 2026, to oversee its legal and compliance functions.
Her responsibilities include corporate governance, and she will report to the President and Chief Executive Officer. Ostrovsky brings 20 years of legal experience and most recently served as General Counsel and Chief Compliance Officer at Deciphera Pharmaceuticals. Candel plans to submit a Biologics License Application, a request for regulatory approval, for aglatimagene besadenovec in intermediate- to high-risk localized prostate cancer in the fourth quarter of 2026, while building capabilities for potential commercialization if approved.
Candel Therapeutics (CADL) will present two accepted posters at the SITC Annual Meeting, taking place November 4–8, 2026, in Phoenix, Arizona.
The November 6 poster covers aglatimagene besadenovec in non-small cell lung cancer progressing despite immune checkpoint inhibitor treatment. The November 7 poster covers clinical and mechanistic findings from the phase 1b trial of linoserpaturev in recurrent glioblastoma.
Candel Therapeutics (CADL) granted stock options covering 85,900 common shares to four new employees on September 30, 2026.
The options have a $10.44 per-share exercise price and were granted under the company's 2025 Inducement Plan as employment inducements under Nasdaq Listing Rule 5635(c)(4). Each award vests 25% on the first anniversary of the employee's start date, with the remaining 75% vesting in 36 equal monthly installments thereafter. All vesting requires continued service through the applicable vesting date.
Candel Therapeutics (CADL) published final phase 2a results showing median overall survival of 24.5 months in evaluable patients with advanced lung cancer. The peer-reviewed study covered 46 evaluable patients with unresectable stage III/IV non-small cell lung cancer and inadequate response to immune checkpoint inhibitors. Patients received aglatimagene besadenovec plus valacyclovir with continued inhibitor therapy. Historical docetaxel survival benchmarks were 9.8–11.8 months, not a concurrent comparison.
Median survival was 21.5 months among 41 patients with disease progression at baseline and 25.4 months among their 33 non-squamous cases. Reduction of uninjected lesions occurred in 69% of 35 evaluable patients with multiple lesions. Grade 3 treatment-related adverse events occurred in 13.7%; no dose-limiting toxicities or unexpected safety signals were identified. The phase 3 AURORA trial is enrolling globally.